Special Issue

Cancer Antibodies

Message from the Guest Editor

I suggest reviewing the following topics:

- Checkpoint regulators and the combinations thereof. The first generation one-mAb-one-target paradigm struggles in the face of tumour heterogeneity and evolution. In contrast, the checkpoint regulator mAbs aim to reactivate the patient's own cellular immune response in tumour microenvironment in an effort to eradicate tumour cells displaying *any* neoantigens, hence potentially benefiting a much wider range of patients.
- T cell engagers: Bispecific engineered antibody-based molecules aim to re-direct and trigger response of cytotoxic T cells of any specificity by cross-linking them to the tumour cells displaying a specific surface protein target or a MHC–peptide complex.
- CARs and TRUCKs: tumour-specific antibody fragments displayed on engineered cytotoxic T cell surface
- Bispecific antibodies for more nuanced tumour cell targeting where binding is limited only to cells expressing a combination of two different targets, not just one or the other. As a result, significantly reduced off-target bystander cell damage can be expected.

Guest Editor

Dr. Armin Sepp

Scientific Leader and GSK Associate Fellow, Systems Modeling and Translational Biology, Glaxo Medicines Research Centre 1F307, Gunnels Wood Road, GlaxoSmithKline Plc, Stevenage SG1 2NY, UK

Deadline for manuscript submissions

closed (15 September 2017)

Antibodies

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed

mdpi.com/si/9332

Antibodies
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibodies@mdpi.com

mdpi.com/journal/antibodies

Antibodies

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.5
Indexed in PubMed

mdpi.com/journal/antibodies

About the Journal

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Editor-in-Chief

Prof. Dr. Arne Skerra
Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

CiteScore - Q2 (Drug Discovery)

MDPI